Communications medicine · 2025
Cross reactivity within pneumococcal serogroups 6 and 15 following adult vaccination with pneumococcal conjugate vaccine V116.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jianing, Platt Heather L, Hu Wenyu, Xu Weifeng, Chapman Timothy J, Nolan Katrina M, Hartzel Jonathan, Buchwald Ulrike K
Аннотация
BACKGROUND: Pneumococcal conjugate vaccines (PCVs) are designed to induce serotype-specific antibodies; however, antibodies raised against pneumococcal polysaccharides in the vaccine can also cross-react to other serotypes based on structural similarities. Cross-reactivity has been demonstrated for some licensed PCVs and is a worthy consideration to broaden protection against pneumococcal disease. This secondary analysis examined cross-reactive immune responses within serogroups 6 and 15 following vaccination with V116, an adult-specific PCV.
METHODS: Antibody levels were assessed across five phase 3 clinical studies at baseline and 30 days following vaccination.
RESULTS: V116 elicits functional antibodies to vaccine serotypes 6A and 15C that result in cross-reactive antibodies to serotypes 6C and 15B, respectively, as assessed by opsonophagocytic activity responses from pre- to post-vaccination and IgG geometric mean concentrations.
CONCLUSIONS: V116-induced antibodies demonstrate cross-reactivity to serotypes 6C and 15B, suggesting protective immune responses may be raised against these non-vaccine serotypes.
METHODS: Antibody levels were assessed across five phase 3 clinical studies at baseline and 30 days following vaccination.
RESULTS: V116 elicits functional antibodies to vaccine serotypes 6A and 15C that result in cross-reactive antibodies to serotypes 6C and 15B, respectively, as assessed by opsonophagocytic activity responses from pre- to post-vaccination and IgG geometric mean concentrations.
CONCLUSIONS: V116-induced antibodies demonstrate cross-reactivity to serotypes 6C and 15B, suggesting protective immune responses may be raised against these non-vaccine serotypes.